- Tralokinumab, an anti-interleukin (IL)-13 antibody, is associated with early and sustained improvements in patients with atopic dermatitis (AD) in a phase 2b study.
Why this matters
- Tralokinumab represents a promising new treatment option for AD and is now in phase 3 trials.
- Tralokinumab was associated with greater improvements in the Eczema Area Severity Index (EASI) compared with placebo at week 12 (adjusted mean difference, −4.94 [P=.01] for 300 mg and −4.36 [P=.03] for 150 mg).
- Tralokinumab was nonsignificantly associated with a higher rate of Investigator’s Global Assessment response (0/1 score and reduction of ≥2 grades from baseline) at week 12 (26.7% vs 11.8% [P=.06] for 300 mg).
- Tralokinumab was associated with higher rates of ≥50% improvement in EASI (EASI50, 73.4% vs 51.9% [P=.03] for 300 mg) and EASI75 (42.5% vs 15.5% [P=.003] for 300 mg) compared with placebo.
- 17.6% of participants reported drug-related treatment-emergent adverse events.
- 204 patients with AD were randomly assigned to receive tralokinumab 45 mg (n=50), 150 mg (n=51), 300 mg (n=52), or placebo (n=51) for 12 weeks with concomitant glucocorticoids and analyzed for efficacy and safety outcomes.
- Funding: MedImmune, a member of the AstraZeneca Group.
- No active comparator.